These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24209715)

  • 1. Potential drug-drug interactions in pediatric outpatient prescriptions for newborns and infants.
    Yeh ML; Chang YJ; Yeh SJ; Huang LJ; Yen YT; Wang PY; Li YC; Hsu CY
    Comput Methods Programs Biomed; 2014; 113(1):15-22. PubMed ID: 24209715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically important potential drug-drug interactions in outpatient settings.
    Aparasu R; Baer R; Aparasu A
    Res Social Adm Pharm; 2007 Dec; 3(4):426-37. PubMed ID: 18082877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicians' responses to computerized drug-drug interaction alerts for outpatients.
    Yeh ML; Chang YJ; Wang PY; Li YC; Hsu CY
    Comput Methods Programs Biomed; 2013 Jul; 111(1):17-25. PubMed ID: 23608682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying high risk medications causing potential drug-drug interactions in outpatients: A prescription database study based on an online surveillance system.
    Toivo TM; Mikkola JA; Laine K; Airaksinen M
    Res Social Adm Pharm; 2016; 12(4):559-68. PubMed ID: 26459026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Countrywide prevalence of critical drug interactions in Hungarian outpatients: a retrospective analysis of pharmacy dispensing data.
    Somogyi-Végh A; Ludányi Z; Erdős Á; Botz L
    BMC Pharmacol Toxicol; 2019 May; 20(1):36. PubMed ID: 31151485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two databases to detect potential drug-drug interactions between prescriptions of HIV/AIDS patients in critical care.
    Ramos GV; Guaraldo L; Japiassú AM; Bozza FA
    J Clin Pharm Ther; 2015 Feb; 40(1):63-7. PubMed ID: 25329640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-label prescribing in pediatric outpatients.
    Palmaro A; Bissuel R; Renaud N; Durrieu G; Escourrou B; Oustric S; Montastruc JL; Lapeyre-Mestre M
    Pediatrics; 2015 Jan; 135(1):49-58. PubMed ID: 25511119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999.
    Guédon-Moreau L; Ducrocq D; Duc MF; Quieureux Y; L'Hôte C; Deligne J; Caron J
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):689-95. PubMed ID: 14557905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study.
    Lin CF; Wang CY; Bai CH
    Drugs Aging; 2011 Mar; 28(3):219-25. PubMed ID: 21250763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
    Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
    Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.
    Ko Y; Tan SL; Chan A; Wong YP; Yong WP; Ng RC; Lim SW; Salim A
    Clin Ther; 2012 Aug; 34(8):1696-704. PubMed ID: 22795926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically relevant potential drug-drug interactions among outpatients: A nationwide database study.
    Jazbar J; Locatelli I; Horvat N; Kos M
    Res Social Adm Pharm; 2018 Jun; 14(6):572-580. PubMed ID: 28716467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy.
    Gagne JJ; Maio V; Rabinowitz C
    J Clin Pharm Ther; 2008 Apr; 33(2):141-51. PubMed ID: 18315779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999.
    Guédon-Moreau L; Ducrocq D; Duc MF; Quieureux Y; L'Hôte C; Deligne J; Caron J
    Eur J Clin Pharmacol; 2004 Feb; 59(12):899-904. PubMed ID: 14685802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing controlled substance prescribing errors in a pediatric teaching hospital: an analysis of the safety of analgesic prescription practice in the transition from the hospital to home.
    Lee BH; Lehmann CU; Jackson EV; Kost-Byerly S; Rothman S; Kozlowski L; Miller MR; Pronovost PJ; Yaster M
    J Pain; 2009 Feb; 10(2):160-6. PubMed ID: 19010736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand.
    Janchawee B; Wongpoowarak W; Owatranporn T; Chongsuvivatwong V
    J Clin Pharm Ther; 2005 Feb; 30(1):13-20. PubMed ID: 15659000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ["Off-label" prescribing of drugs in the ambulatory care of children and adolescents].
    Bücheler R; Meisner C; Kalchthaler B; Mohr H; Schröder H; Mörike K; Schwoerer P; Schwab M; Gleiter CH
    Dtsch Med Wochenschr; 2002 Nov; 127(48):2551-7. PubMed ID: 12457324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers.
    Ko Y; Malone DC; Skrepnek GH; Armstrong EP; Murphy JE; Abarca J; Rehfeld RA; Reel SJ; Woosley RL
    Drug Saf; 2008; 31(6):525-36. PubMed ID: 18484786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Off-label drug prescriptions among outpatient children and adolescents in Germany--a database analysis].
    Sonntag D; Trebst D; Kiess W; Kapellen T; Bertsche T; Kostev K
    Dtsch Med Wochenschr; 2013 Oct; 138(44):2239-45. PubMed ID: 24150699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usage of the claim database of national health insurance programme for analysis of cisapride-erythromycin co-medication in Taiwan.
    Gau CS; Chang IS; Lin Wu FL; Yu HT; Huang YW; Chi CL; Chien SY; Lin KM; Liu MY; Wang HP
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):86-95. PubMed ID: 17006967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.